Case report

Intracranial solitary fibrous tumor/hemangiopericytoma mimicking cystic meningioma: A case report and literature review✩

Tomonori Chikasue, MDa,*, Yusuke Uchiyama, MD, PhD, Shuichi Tanoue, MD, PhD, Satoru Komaki, MD, PhDb, Yasuo Sugita, MD, Phdc, Toshi Abe, MD, Phdd

aDepartment of Radiology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan
bDepartment of Neurosurgery, Kurume University School of Medicine, Kurume, Japan
cDepartment of Neuropathology, St. Mary's Hospital, Kurume, Japan

dArticle history:
Received 20 December 2020
Revised 2 April 2021
Accepted 2 April 2021

Keywords:
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC)
Meningioma
Diffusion-weighted imaging

A B S T R A C T

Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a relatively rare type of tumor that originates from meningeal mesenchyme. A 30-year-old man presented leaning his body to the left and with weakness of his left lower limb. Computed tomography revealed a heterogeneous mass with multiple cystic components and hyperostosis of the right cranial convexity. Magnetic resonance imaging showed the mass was broadly attached to the dura matter with dural tail sign. In addition, the lesion had extensive cystic degeneration and a solid compartment showing low apparent diffusion coefficient values. The patient underwent gross total resection of the intracranial lesion and presented no recurrence within a 12-month follow-up period. Histopathology confirmed SFT/HPC (World Health Organization grade II). Although there have been several useful techniques reported to differentiate SFT/HPC from meningioma, in this case the atypical findings for SFT/HPC made it difficult. We report the imaging findings of this case and some literature reviews.

© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) originates from meningeal mesenchyme. It is a rare type of tumor and makes up less than 1% of all intracranial neoplasms [1–3]. Because SFT/HPC and meningiomas present with similar imaging findings, they are often difficult to differentiate [4,5]. However, they do require significantly different treatment methods and surgical planning and have significantly different prognoses. Compared with meningioma, SFT/HPC has a much more aggressive biological behavior, and it often recurs after surgical resection (60%) and metastasizes to extracranial organs (20%) [2,6]. Therefore, in order to determine an appropriate treatment, it is important to differentiate between SFT/HPC and meningioma. We report

✩ Competing Interests: The authors declare no conflicts of interest associated with this manuscript.
Correspondence author. T. Chikasue.
E-mail address: chikasue_tomonori@med.kurume-u.ac.jp (T. Chikasue).
https://doi.org/10.1016/j.radcr.2021.04.008
1930-0433/© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
a case of SFT/HPC, which was difficult to distinguish from meningioma based on imaging findings, with some literature review.

Case report

A 30-year-old man had been taking internal medicine for schizophrenia, prescribed by a local doctor, for 6 years. He presented with his body leaning to the left and weakness in the left upper and lower limbs. A head computed tomography was performed, which revealed a mass in the cranium, and he was referred to our hospital for neurosurgical treatment.

At our hospital, he presented with impaired consciousness (Japan Coma Scale-1, Glasgow Coma Scale E4V5M5). Left facial nerve palsy and dysarthria were observed, and muscle strength of the left upper and lower limbs was reduced (Manual Muscle Test left upper limbs, 3/5; left lower limbs, 3/5). Biochemical investigations were unremarkable.

Non-enhanced computed tomography (Fig. 1) revealed a 3.5 × 9.3 × 7.4 cm solid and cystic mass adjacent to the right temporal lobe attached to the right cranial convexity. The solid part showed higher attenuation than the gray matter. The tumor showed the remarkable mass effect with the midline shift from the right side to the left, and the midbrain was also highly compressed with a risk of transtentorial hernia. The temporal bone bordering the lesion showed bony thickening, which was considered to be a finding of hyperostosis.

Magnetic resonance imaging (Fig. 2) demonstrated an extra axial tumor attached to the right cranial convexity with an oval shape and a well-defined margin. Mild edema was also observed in the temporal lobe, and there were extensive polycystic components in the anterior half of the lesion. The solid partitions demonstrated iso- to high intense on a T1-weighted image (T1WI) and low to slightly high on a T2-weighted image (T2WI) in comparison with cortical gray matter. Cystic areas and signal void vessels were also observed in the lesion. Post-contrast enhanced T1WI showed heterogeneous mild to well-defined enhancement with the dural tail sign. Corresponding apparent diffusion coefficient (ADC) maps showed relatively restricted diffusion (minimum ADC value = 0.79 × 10⁻³ mm²/s).

Because of the dural tail sign and hyperostosis, the cystic component occupying nearly half of the lesion, and the low ADC value in the solid area, we suspected a cystic meningioma. The lesion had a marked mass effect with a risk of transtentorial hernia, and it was promptly removed. The patient underwent gross total resection of the intracranial lesion, and he tolerated the procedure well; his symptoms and clinical effect improved postoperatively. A postoperative MRI confirmed gross total resection. Twelve months have passed without recurrence since the operation.

On microscopic examination (Fig. 3), his tumor cells exhibited a diffuse growth pattern with abundant slit-shaped vessels in the central area. Silver staining revealed linear structures that were thought to be collagen fibers. Mitosis exceeded 5 or less in 10 high power fields. Immunohistochemistry examination was positive for vimentin, signal transducer and activator of transcription 6 (STAT6), and CD34 and negative for epithelial membrane antigen, S-100, CD31, desmin, CK41, A3, and glial fibrillary acidic protein. Ki-67 staining showed a proliferative index of 15%. These findings led to a diagnosis of SFT/HPC (World Health Organization [WHO] grade II, HPC phenotype).

Discussion

The 2016 Central Nervous System WHO update merged the entities of meningeal SFT/HPC into a single entity based on the presence of the nerve growth factor 1A binding protein 2-STAT6 gene fusion in these tumors. In our case, immunohistochemical staining with STAT6 resulted in a strong nuclear positivity, confirming the diagnosis [1].

SFT/HPC and meningioma exhibit similar radiological features; however, their prognoses are different. SFT/HPC
is much more biologically aggressive and often recurs after surgical resection (60%) and metastasizes to extracranial organs (20%) [2,6]. In order to determine treatment and follow-up, it is important to differentiate between the 20 preoperatively.

In general, SFT/HPC appears as isointense to slightly high on T1WI and as isointense on T2WI, compared with gray matter. Conversely, meningiomas are usually hypo- to isointense compared with the cerebral cortex on T1WI and iso- to hyperintense on T2WI. There are some imaging features that can be used to differentiate SFT/HPC from meningioma. Specifically, less frequent calcification, a narrow-based attachment, lack of dural tail sign, and frequent presentation of “flow void” sign are more frequent in SFT/HPC than in meningioma. SFT/HPC tends to be aggressive, with behavior such as apparent parenchymal invasion, irregular or multi-lobulated borders, bone erosion, and heterogeneous contrast enhancement. However, these imaging features cannot be used to reliably differentiate SFT/HPC from meningioma, and previous studies have reported a low diagnostic rate accuracy [7-15]. In the
Fig. 3 – Histological findings

(A–C) H&E stain (A, 40 x; B, 100 x; C, 400 x) showed tumor cells presenting a diffuse growth pattern with abundant slit-shaped vessels in the central area. Ten high power fields (400 x) revealed mitosis 5 or less (white arrow).

(D) Silver staining (100 x) revealed linear structures indicating collagen fibers.

(E–H) Immunohistochemistry examination of vimentin (E, 100 x), STAT6 (F, 100 x), and CD34 (G, 100 x) was positive. Ki-67 staining (H, 100 x) showed a proliferative index of 15%. No other immunostainings were positive.
present case, the dural tail sign and hyperostosis made it difficult to differentiate SFT/HPC from meningioma.

Meningiomas characteristically demonstrate iso- to hypointensity on T1WI and iso- to hyperintensity on T2WI compared with gray matter [16]. Some meningiomas may appear as hyperintense on T1WI. High signal intensity on T1WI in meningiomas is thought to be associated with hemorrhage, high lipid content in tumor cells, and calcification. Thus, lipomatous meningioma is a histological variant of meningiomas that shows hyperintensity on T1WI [17,18]. The present case presented hyperintensity on T1WI compared with gray matter, but it was not fat, hemorrhage, or calcification, and therefore, with respect to the T1WI signal, this finding may have been more suggestive of SFT/HPC than meningioma.

Approximately 3%-5% of adult meningiomas are so-called “cystic meningiomas,” which are meningiomas with a cystic component [19–21]. Although cases of HPC with cystic degeneration have been reported [22], there have been few reports [23,24] of cystic degeneration in nearly half of the lesions, as in this case. Widespread cystic degeneration may be 1 factor that makes the differentiation between SFT/HPC and meningioma difficult.

There are several reports comparing ADC between SFT/HPC and meningioma. Liu et al. [25] found a significant difference, with min ADC of 1.116 (±0.127) × 10⁻³ mm²/s for HPC and 0.875 (±0.104) × 10⁻³ mm²/s for meningioma. Jai et al. [26] reported that there was a significant difference between HPC and meningioma in mean ADC (1.163.23 ± 134.47 mm²/s for SFT/HPC and 863.94 ± 63.55 mm²/s for meningioma) but not in min ADC.

On the other hand, some reports suggest that ADC values are variable depending on the histological system of the meningioma and the grade of the SFT/HPC. Liu et al. [27] compared the ADC levels of HPC and angiomatosus and anaplastic (WHO grade III) meningiomas. Mean ADC values were significantly different between HPC and anaplastic meningioma (1.17 ± 0.30 × 10⁻³ mm²/s and 0.75 ± 0.11 × 10⁻³ mm²/s, respectively). Mean ADC values did not differ significantly between angiomatosus meningioma and HPC (the ADC value of angiomatosus meningioma was 1.23 ± 0.25 × 10⁻³ mm²/s, P > 0.05). Furthermore, Kanazawa et al. [28] reported the mean ADC value of meningioma was significantly high in angiomatosus meningioma compared with SFT/HPC and other WHO grade I meningioma (1.214 ± 0.213 × 10⁻³ mm²/s, 0.972 ± 0.154 × 10⁻³ mm²/s, and 0.941 ± 0.119 × 10⁻³ mm²/s, respectively). Mama [29] reported that all grade II HPCs showed higher ADC values than grade III (range 1.26–1.50 × 10⁻³ mm²/s and 0.638–0.833 × 10⁻³ mm²/s, respectively).

According to previous reports, most of which were on HPC phenotype, ADC values, which vary depending on the histological type and grade, are generally higher in SFT/HPC than in meningioma. Therefore, these values might be better used only as a reference for the differentiation of SFT/HPC and meningioma.

In conclusion, differentiating SFT/HPC from meningioma is sometimes difficult. Our case of SFT/HPC with multiple findings suggesting meningioma, including dural tail sign, hyperostosis, extensive cystic degeneration, and relatively low ADC values, appears to be very rare. However, focusing on the T1WI findings might have allowed us to consider SFT/HPC as a differential disease.

Patient consent

Informed consent was obtained from the patient.

References

[1] Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.
[2] Ratneswaran T, et al. Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease. J Neurooncol 2018;138(3):447–67. doi:10.1007/s11060-018-2836-2.
[3] Kinslow CJ, et al. Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. J Neurooncol 2018;138(1):173–82 DOI: 10.1002/jon.21233.10.1007/1097-0142(19930801)72:3<639::Aid-cncr2820720304>3.0.co;2-p. doi:10.1106/j.clinicneuro.2015.08.005.
[5] Smith AB, et al. From the radiologic pathology archives: mass lesions of the dura: beyond meningioma-radiologic-pathologic correlation. Radiographics 2014;34(2):295–312. doi:10.1148/rg.342130075.
[6] Chiachi MV, et al. Intracranial hemangiopericytomas: MR and CT features. AJNR Am J Neuroradiol 1996;17(7):1365–71 PMID: 8871726.
[7] Huang RY, et al. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol 2019;21(Suppl 1):i44–61. doi:10.1093/neuonc/nyz143.
[8] Cosentino CM, et al. Giant cranial hemangiopericytoma: MR and angiographic findings. AJNR Am J Neuroradiol 1993;14(1):253–6 PMID: 8427100.
[9] Alén JF, et al. Intracranial hemangiopericytoma: study of 12 cases. Acta Neurochir (Wien) 2001;143(6):575–86. doi:10.1007/s007010170062.
[10] Fountas KN, et al. Management of intracranial meningeal hemangiopericytomas: outcome and experience. Neurosurg Rev 2006;29(2):145–53 Epub 2006 Jan 4. doi:10.1007/s10143-005-0009-1.
[11] Wu W, et al. Hemangiopericytomas in the central nervous system. J Clin Neurosci 2009;16(4):519–23. doi:10.1016/j.jocn.2008.06.011.
[12] Brunori A, et al. Recent experience in the management of meningeal hemangiopericytomas. Tumori 1997;83(5):856–61 PMID: 9428922.
[13] Younis GA, et al. Aggressive meningeal tumors: review of a series. J Neurosurg 1995;82(1):17–27. doi:10.3171/jns.1995.82.1.0017.
[14] Payne BR, et al. Gamma surgery for hemangiopericytomas. Acta Neurochir (Wien) 2000;142(5):527–36 discussion 536-7. doi:10.1007/s007060050465.
[15] Osborne DR, et al. Primary intracranial meningeal and spinal hemangiopericytoma: radiologic manifestations. AJNR Am J Neuroradiol 1981;2(1):69–74 PMID: 6784553.
[16] Buetow M P, et al. Typical, atypical, and misleading features in meningioma. Radiographics 1991;11(6):1087–106. doi:10.1148/radiographics.11.6.1749851.

[17] Cakirer Sinan, et al. Spontaneously T1-hyperintense lesions of the brain on MRI: a pictorial review. Curr Probl Diagn Radiol 2003;32(5):194–217. doi:10.1016/s0363-0188(03)00026-4.

[18] Maiuri F, et al. Intracranial meningiomas: correlations between MR imaging and histology. Eur J Radiol 1999;31(1):69–75. doi:10.1016/s0720-048x(98)00083-7.

[19] De Jesus O, et al. Cystic meningiomas: a review. Neurosurgery 1995;36(3):489–92. doi:10.1227/00006123-199503000-00007.

[20] Boukobza M, et al. Cystic meningioma: radiological, histological, and surgical particularities in 43 patients. Acta Neurochir (Wien) 2016;158(10):1955–64. doi:10.1007/s00701-016-2898-x.

[21] Amin OS, et al. Cystic meningioma. BMJ Case Rep 2015 2015 Feb 10. doi:10.1136/bcr-2014-207690.

[22] Spatola C, et al. Recurrent intracranial hemangiopericytoma with extracranial and unusual multiple metastases: case report and review of the literature. Tumori 2004;90(2):265–8. PMID: 15237597.

[23] Pang H, et al. Morphologic patterns and imaging features of intracranial hemangiopericytomas: a retrospective analysis. Onco Targets Ther 2015;8:2169–78. doi:10.2147/OTT.S85971.

[24] Li X, et al. Magnetic resonance features of meningeal solitary fibrous tumors. Oncol Lett 2018;15(6):8825–32. doi:10.3892/ol.2018.8426.

[25] Liu G, et al. Intracranial hemangiopericytoma: MR imaging findings and diagnostic usefulness of minimum ADC values. J Magn Reson Imaging 2013;38(5):1146–51. doi:10.1002/jmri.24075.

[26] Shankar Jai Jai Shiva, et al. Diffusion weighted imaging may help differentiate intracranial hemangiopericytoma from meningioma. J Neuroradiol 2019;46(4):263–7. doi:10.1016/j.neurad.2018.11.002.

[27] Liu L, et al. Comparison of ADC values of intracranial hemangiopericytomas and angiomatous and anaplastic meningiomas. J Neuroradiol 2014;41(3):188–94. doi:10.1016/j.neurad.2013.07.002.

[28] Kanazawa Tokunori, et al. Preoperative prediction of solitary fibrous tumor/hemangiopericytoma and angiomatous meningioma using magnetic resonance imaging texture analysis. World Neurosurg 2018;120:e1208–16.

[29] Mama N, Ben Abdallah A, Hasni I, Kadri K, Arifa N, Ladib M, et al. MR imaging of intracranial hemangiopericytomas. J Neuroradiol 2014;41(5):296–306. doi:10.1016/j.neurad.2013.10.007.